In the latest quarter, 13 analysts provided ratings for Ionis Pharmaceuticals (NASDAQ:IONS), showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $61.08, accompanied by a high estimate of $75.00 and a low estimate of $37.00. This upward trend is evident, with the current average reflecting a 10.89% increase from the p…